Effect of peroxisome proliferator-activated receptor γ on the cholesterol efflux of peritoneal macrophages in inflammation

He,Kun; Li,Yue; Yang,Kang; Gong,Jian-Ping; Li,Pei-Zhi

doi:10.3892/mmr.2014.2200

Effect of peroxisome proliferator-activated receptor γ on the cholesterol efflux of peritoneal macrophages in inflammation

Authors:
- Kun He
- Yue Li
- Kang Yang
- Jian-Ping Gong
- Pei-Zhi Li
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, P.R. China
Published online on: April 29, 2014 https://doi.org/10.3892/mmr.2014.2200
Pages: 373-378

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Atherosclerosis, a chronic inflammatory disorder characterized by lipid and cholesterol accumulation, is the principal contributing factor to the pathology of cardiovascular disease. Macrophages contribute to plaque development by internalizing native and modified lipoproteins that convert them into cholesterol-rich foam cells. With multiple factors, including hypercholesterolemia and inflammation, promoting atherosclerosis, it is of great significance to elucidate how the mechanism of cholesterol efflux from the macrophages changes and the role of peroxisome proliferator-activated receptor γ (PPARγ) in these situations. Following isolation and culture of peritoneal macrophages from C57BL/6 mice in the present study, the cells were divided into three groups: The control group, the ciglitazone group and the PPARγ antisense oligonucleotide group. The expression of PPARγ and nuclear factor of κ light polypeptide gene enhancer in B‑cells inhibitor α (IκBα) in each group was observed through the levels of protein and mRNA, and then the cholesterol efflux of each group was investigated. In addition, the same experiments were repeated following stimulation of each group with lipopolysaccharide (LPS). No significant difference in the expression levels of PPARγ between the control group and ciglitazone group was observed. The expression levels of PPARγ in the PPARγ antisense oligonucleotide group were evidently lower than those in the control group. Subsequent to stimulation with LPS, the expression levels of PPARγ in the three groups were higher than those of each group prior to stimulation. The cholesterol efflux of the PPARγ antisense oligonucleotide group was clearly suppressed following stimulation with LPS in comparison with that of the other groups. PPARγ contributes to anti-inflammation by protecting IκBα from being phosphorylated and degraded and promoting cholesterol efflux from peritoneal macrophages in inflammation.

View Figures

View References

1	Klingenberg R and Hansson GK: Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur Heart J. 30:2838–2844. 2009. View Article : Google Scholar : PubMed/NCBI
2	Moore KJ and Tabas I: Macrophages in the pathogenesis of atherosclerosis. Cell. 145:341–355. 2011. View Article : Google Scholar
3	Hansson GK and Hermansson A: The immune system in atherosclerosis. Nat Immunol. 12:204–212. 2011. View Article : Google Scholar : PubMed/NCBI
4	Reiss AB and Cronstein BN: Regulation of foam cells by adenosine. Arterioscler Thromb Vasc Biol. 32:879–886. 2012. View Article : Google Scholar : PubMed/NCBI
5	McLaren JE, Michael DR, Ashlin TG and Ramji DP: Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog Lipid Res. 50:331–347. 2011. View Article : Google Scholar : PubMed/NCBI
6	Glass CK and Saijo K: Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol. 10:365–376. 2010. View Article : Google Scholar : PubMed/NCBI
7	Villacorta L, Schopfer FJ, Zhang J, et al: PPARgamma and its ligands: therapeutic implications in cardiovascular disease. Clin Sci (Lond). 116:205–218. 2009. View Article : Google Scholar : PubMed/NCBI
8	Bouhlel MA, Staels B and Chinetti-Gbaguidi G: Peroxisome proliferator-activated receptors - from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease. J Intern Med. 263:28–42. 2008.
9	Rigamonti E, Chinetti-Gbaguidi G and Staels B: Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. Arterioscler Thromb Vasc Biol. 28:1050–1059. 2008. View Article : Google Scholar : PubMed/NCBI
10	Tabas I: Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol. 10:36–46. 2010. View Article : Google Scholar : PubMed/NCBI
11	Martinez FO, Helming L and Gordon S: Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol. 27:451–483. 2009. View Article : Google Scholar : PubMed/NCBI
12	Takano H and Komuro I: Peroxisome proliferator-activated receptor gamma and cardiovascular diseases. Circ J. 73:214–220. 2009. View Article : Google Scholar : PubMed/NCBI
13	Lamers C, Schubert-Zsilavecz M and Merk D: Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008-present). Expert Opin Ther Pat. 22:803–841. 2012. View Article : Google Scholar : PubMed/NCBI
14	Kajinami K and Kawai Y: Beyond C-reactive protein; new evidence for another inflammatory biomarker predicting cardiovascular disease risk. Atherosclerosis. 214:39–40. 2011. View Article : Google Scholar : PubMed/NCBI
15	Lawrence CB, Brough D and Knight EM: Obese mice exhibit an altered behavioural and inflammatory response to lipopolysaccharide. Dis Model Mech. 5:649–659. 2012. View Article : Google Scholar : PubMed/NCBI
16	Lloyd-Jones D, Adams RJ, Brown TM, et al: American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Executive summary: heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation. 121:948–954. 2010. View Article : Google Scholar
17	Zhao Y, Pennings M, Vrins CL, et al: Hypocholesterolemia, foam cell accumulation, but no atherosclerosis in mice lacking ABC-transporter A1 and scavenger receptor BI. Atherosclerosis. 218:314–322. 2011. View Article : Google Scholar : PubMed/NCBI
18	Uto-Kondo H, Ayaori M, Ogura M, et al: Coffee consumption enhances high-density lipoprotein-mediated cholesterol efflux in macrophages. Circ Res. 106:779–787. 2010. View Article : Google Scholar : PubMed/NCBI
19	Ogawa Y, Yoneda M, Tomeno W, et al: Peroxisome proliferator-activated receptor gamma exacerbates Concanavalin A-induced liver injury via suppressing the translocation of NF-κB into the nucleus. PPAR Res. 2012:9403842012.PubMed/NCBI
20	Norazmi MN, Mohamed R, Nurul AA and Jaacob NS: The modulation of PPARγ1 and PPARγ2 mRNA expression by ciglitazone in CD3/CD28-activated naïve and memory CD4⁺ T cells. Clin Dev Immunol. 2012:8491952012.
21	Tobiasova Z, Zhang L, Yi T, et al: Peroxisome proliferator-activated receptor-γ agonists prevent in vivo remodeling of human artery induced by alloreactive T cells. Circulation. 124:196–205. 2011.
22	Visser ME, Witztum JL, Stroes ES and Kastelein JJ: Antisense oligonucleotides for the treatment of dyslipidaemia. Eur Heart J. 33:1451–1458. 2012. View Article : Google Scholar : PubMed/NCBI
23	Robinson SM and Mann DA: Role of nuclear factor kappaB in liver health and disease. Clin Sci (Lond). 118:691–705. 2010. View Article : Google Scholar : PubMed/NCBI
24	Tornatore L, Thotakura AK, Bennett J, et al: The nuclear factor kappa B signaling pathway: integrating metabolism with inflammation. Trends Cell Biol. 22:557–566. 2012. View Article : Google Scholar : PubMed/NCBI
25	Kwak JH, Jung JK and Lee H: Nuclear factor-kappa B inhibitors; a patent review (2006–2010). Expert Opin Ther Pat. 21:1897–1910. 2011.
26	Kim IT, Ryu S, Shin JS, et al: Euscaphic acid isolated from roots of Rosa rugosa inhibits LPS-induced inflammatory responses via TLR4-mediated NF-κB inactivation in RAW 264.7 macrophages. J Cell Biochem. 113:1936–1946. 2012.PubMed/NCBI
27	Bright JJ, Kanakasabai S, Chearwae W and Chakraborty S: PPAR regulation of inflammatory signaling in CNS diseases. PPAR Res. 2008:6585202008. View Article : Google Scholar : PubMed/NCBI
28	Hirsch J, Johnson CL, Nelius T, et al: PEDF inhibits IL8 production in prostate cancer cells through PEDF receptor/phospholipase A2 and regulation of NFκB and PPARγ. Cytokine. 55:202–210. 2011.PubMed/NCBI
29	Simone RE, Russo M, Catalano A, et al: Lycopene inhibits NF-κB-mediated IL-8 expression and changes redox and PPARγ signalling in cigarette smoke-stimulated macrophages. PLoS One. 6:e196522011.
30	Fan B, Ikuyama S, Gu JQ, et al: Oleic acid-induced ADRP expression requires both AP-1 and PPAR response elements, and is reduced by Pycnogenol through mRNA degradation in NMuLi liver cells. Am J Physiol Endocrinol Metab. 297:E112–123. 2009. View Article : Google Scholar : PubMed/NCBI